Imbalance of the nerve growth factor and its precursor as a potential biomarker for diabetic retinopathy

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Mysona, B A ^a,b,c   Matragoon, S ^a,b,c   Stephens, M ^b   Mohamed, I N ^a,b,c   Farooq, A ^a,b,c   Bartasis, M L ^a,b,c   Fouda, A Y ^a,b,c   Shanab, A Y ^a,b,c   Espinosa Heidmann, D G ^b   El Remessy, A B ^a,b,c  

^a UNIVERSITY OF GEORGIA   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MATRILYSIN; NERVE GROWTH FACTOR; PRO NERVE GROWTH FACTOR; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; NGF PROTEIN, HUMAN; PROTEIN PRECURSOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DIABETIC RETINOPATHY; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; MIDDLE AGED; RETINA; VITRECTOMY; VITREOUS BODY; WESTERN BLOTTING; YOUNG ADULT; ADOLESCENT; ANIMAL; BLOOD; CASE CONTROL STUDY; DIABETES MELLITUS; EXPERIMENTAL DIABETES MELLITUS; GEORGIA; METABOLISM; PILOT STUDY;

ADOLESCENT; ADULT; AGED; ANIMALS; BIOMARKERS; CASE-CONTROL STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; FEMALE; GEORGIA; HUMANS; MALE; MIDDLE AGED; NERVE GROWTH FACTOR; PILOT PROJECTS; PROTEIN PRECURSORS; RETINA; YOUNG ADULT;

EID: 84926482978     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/571456     Document Type: Article

References (62)

1. J. W. Y. Yau, S. L. Rogers, R. Kawasaki et al., "Global prevalence and major risk factors of diabetic retinopathy," Diabetes Care, Vol. 35, no. 3, pp. 556-564, 2012.
2. K. Miyamoto and Y. Ogura, "Pathogenetic potential of leukocytes in diabetic retinopathy," Seminars in Ophthalmology, Vol. 14, no. 4, pp. 233-239, 1999.
3. J. Cunha-Vaz and R. Bernardes, "Nonproliferative retinopathy in diabetes type 2. Initial stages and characterization of phenotypes," Progress in Retinal and Eye Research, Vol. 24, no. 3, pp. 355-377, 2005.
4. T. Abiko, A. Abiko, A. C. Clermont et al., "Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: role of oxidants and protein kinase-C activation," Diabetes, Vol. 52, no. 3, pp. 829-837, 2003.
5. F. L. Ferris III and A. Patz, "Macular edema. A complication of diabetic retinopathy," Survey of Ophthalmology, Vol. 28, pp. 452-461, 1984.
6. R. Klein, B. E. K. Klein, S. E. Moss, and K. J. Cruickshanks, "The Wisconsin epidemiologic study of diabetic retinopathy XV: the long-term incidence of macular edema," Ophthalmology, Vol. 102, no. 1, pp. 7-16, 1995.
7. L. P. Aiello, R. L. Avery, P. G. Arrigg et al., "Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders," The New England Journal of Medicine, Vol. 331, no. 22, pp. 1480-1487, 1994.
8. J. W. Miller, A. P. Adamis, and L. P. Aiello, "Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy," Diabetes/Metabolism Research and Reviews, Vol. 13, pp. 37-50, 1997.
9. J. F. Arevalo, J. G. Sanchez, A. F. Lasave et al., "Intravitreal bevacizumab (Avastin) for diabetic retinopathy at 24-months: the 2008 juan verdaguer-planas lecture," Current Diabetes Reviews, Vol. 6, no. 5, pp. 313-322, 2010.
10. J. C. S. Yam and A. K. H. Kwok, "Update on the treatment of diabetic retinopathy," Hong Kong Medical Journal, Vol. 13, no. 1, pp. 46-60, 2007.
11. Q. D. Nguyen, D. M. Brown, D. M. Marcus et al., "Ranibizumab for diabetic macular edema: results from 2 phase iii randomized trials: RISE and RIDE," Ophthalmology, Vol. 119, no. 4, pp. 789-801, 2012.
12. "The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial," Diabetes, Vol. 44, pp. 968-983, 1995.
13. J. Cunha-Vaz, L. Ribeiro, and C. Lobo, "Phenotypes and biomarkers of diabetic retinopathy," Progress in Retinal and Eye Research, Vol. 41, pp. 90-111, 2014.
14. J. Cunha-Vaz, "Characterization and relevance of different diabetic retinopathy phenotypes," Developments in Ophthalmology, Vol. 39, pp. 13-30, 2007.
15. S. Nunes, I. Pires, A. Rosa, L. Duarte, R. Bernardes, and J. Cunha-Vaz, "Microaneurysm turnover is a biomarker for diabetic retinopathy progression to clinically significant macular edema: findings for type 2 diabetics with nonproliferative retinopathy," Ophthalmologica, Vol. 223, no. 5, pp. 292-297, 2009.
16. C. Haritoglou, M. Kernt, A. Neubauer et al., "Microaneurysm formation rate as a predictive marker for progression to clinically significant macular edema in nonproliferative diabetic retinopathy," Retina, Vol. 34, no. 1, pp. 157-164, 2014.
17. S. F. Leicht, M. Kernt, A. Neubauer et al., "Microaneurysm turnover in diabetic retinopathy assessed by automated retmarkerDR image analysis - potential role as biomarker of response to ranibizumab treatment," Ophthalmologica, Vol. 231, no. 4, pp. 198-203, 2014.
18. R. Bernardes, S. Nunes, I. Pereira et al., "Computer-assisted microaneurysm turnover in the early stages of diabetic retinopathy," Ophthalmologica, Vol. 223, no. 5, pp. 284-291, 2009.
19. R. Bernardes, T. Santos, P. Serranho, C. Lobo, and J. Cunha-Vaz, "Noninvasive evaluation of retinal leakage using optical coherence tomography," Ophthalmologica, Vol. 226, no. 2, pp. 29-36, 2011.
20. D. J. Browning and C. M. Fraser, "The predictive value of patient and eye characteristics on the course of subclinical diabetic macular edema," American Journal of Ophthalmology, Vol. 145, no. 1, pp. 149.e3-154.e3, 2008.
21. M. A. Bearse Jr., A. J. Adams, Y. Han et al., "A multifocal electroretinogram model predicting the development of diabetic retinopathy," Progress in Retinal and Eye Research, Vol. 25, no. 5, pp. 425-448, 2006.
22. S. Nunes, L. Ribeiro, C. Lobo, and J. Cunha-Vaz, "Three different phenotypes of mild nonproliferative diabetic retinopathy with different risks for development of clinically significant macular edema," Investigative Ophthalmology and Visual Science, Vol. 54, no. 7, pp. 4595-4604, 2013.
23. N. Ogata, M. Nishikawa, T. Nishimura, Y. Mitsuma, and M. Matsumura, "Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy," The American Journal of Ophthalmology, Vol. 134, no. 3, pp. 348-353, 2002.
24. Y. Suzuki, M. Nakazawa, K. Suzuki, H. Yamazaki, and Y. Miyagawa, "Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion," Japanese Journal of Ophthalmology, Vol. 55, no. 3, pp. 256-263, 2011.
25. C. Hernández, M. García-Ramírez, N. Colomé et al., "New pathogenic candidates for diabetic macular edema detected by proteomic analysis," Diabetes Care, Vol. 33, no. 7, p. e92, 2010.
26. H. Wang, L. Feng, J. W. Hu, C. L. Xie, and F. Wang, "Characterisation of the vitreous proteome in proliferative diabetic retinopathy," Proteome Science, Vol. 10, no. 1, article 15, 2012.
27. S. F. Abcouwer, "Angiogenic factors and cytokines in diabetic retinopathy," Journal of Clinical & Cellular Immunology, no. 11, supplement 1, 2013.
28. K. S. Park, S. S. Kim, J. C. Kim et al., "Serum and tear levels of nerve growth factor in diabetic retinopathy patients," The American Journal of Ophthalmology, Vol. 145, no. 3, pp. 432-437, 2008.
29. H. C. Kim, Y. J. Cho, C. W. Ahn et al., "Nerve growth factor and expression of its receptors in patients with diabetic neuropathy," Diabetic Medicine, Vol. 26, no. 12, pp. 1228-1234, 2009.
30. L. Aloe, S. Rossi, and L. Manni, "Altered expression of nerve growth factor and its receptors in the kidneys of diabetic rats," Journal of Nephrology, Vol. 24, no. 6, pp. 798-805, 2011.
31. T. K. Ali, M. M. H. Al-Gayyar, S. Matragoon et al., "Diabetes-induced peroxynitrite impairs the balance of pro-nerve growth factor and nerve growth factor, and causes neurovascular injury," Diabetologia, Vol. 54, no. 3, pp. 657-668, 2011.
32. R. Lee, P. Kermani, K. K. Teng, and B. L. Hempstead, "Regulation of cell survival by secreted proneurotrophins," Science, Vol. 294, no. 5548, pp. 1945-1948, 2001.
33. L. F. Reichardt, "Neurotrophin-regulated signalling pathways," Philosophical Transactions of the Royal Society B: Biological Sciences, Vol. 361, no. 1473, pp. 1545-1564, 2006.
34. E. J. Huang and L. F. Reichardt, "Trk receptors: roles in neuronal signal transduction," Annual Review of Biochemistry, Vol. 72, pp. 609-642, 2003.
35. K. K. Teng, S. Felice, T. Kim, and B. L. Hempstead, "Understanding proneurotrophin actions: recent advances and challenges," Developmental Neurobiology, Vol. 70, no. 5, pp. 350-359, 2010.
36. M. M. Al-Gayyar, S. Matragoon, B. A. Pillai, T. K. Ali, M. A. Abdelsaid, and A. B. El-Remessy, "Epicatechin blocks pro-nerve growth factor (proNGF)-mediated retinal neurodegeneration via inhibition of p75 neurotrophin receptor expression in a rat model of diabetes," Diabetologia, Vol. 54, pp. 669-680, 2011.
37. F. Mantelli, A. Lambiase, V. Colafrancesco, M. L. Rocco, I. Macchi, and L. Aloe, "NGF and VEGF effects on retinal ganglion cell fate: new evidence from an animal model of diabetes," European Journal of Ophthalmology, Vol. 24, no. 2, pp. 247-253, 2013.
38. M. M. H. Al-Gayyar, B. A. Mysona, S. Matragoon et al., "Diabetes and overexpression of proNGF cause retinal neurode-generation via activation of RhoA pathway," PLoS ONE, Vol. 8, no. 1, Article ID e54692, 2013.
39. V. Colafrancesco, M. Coassin, S. Rossi, and L. Aloe, "Effect of eye NGF administration on two animal models of retinal ganglion cells degeneration," Annali dell'Istituto Superiore di Sanita, Vol. 47, no. 3, pp. 284-289, 2011.
40. NTR prevents diabetes- and proNGF-induced retinal inflammation and blood-retina barrier breakdown in mice and rats," Diabetologia, Vol. 56, no. 10, pp. 2329-2339, 2013.
41. K.-M. Jung, S. Tan, N. Landman et al., "Regulated intramembrane proteolysis of the p75 neurotrophin receptor modulates its association with the TrkA receptor," The Journal of Biological Chemistry, Vol. 278, no. 43, pp. 42161-42169, 2003.
42. K. C. Kanning, M. Hudson, P. S. Amieux, J. C. Wiley, M. Bothwell, and L. C. Schecterson, "Proteolytic processing of the p75 neurotrophin receptor and two homologs generates C-terminal fragments with signaling capability," Journal of Neuroscience, Vol. 23, no. 13, pp. 5425-5436, 2003.
43. Y. Wei, N. Wang, Q. Lu, N. Zhang, D. Zheng, and J. Li, "Enhanced protein expressions of sortilin and p75NTR in retina of rat following elevated intraocular pressure-induced retinal ischemia," Neuroscience Letters, Vol. 429, no. 2-3, pp. 169-174, 2007.
44. N. G. Seidah, S. Benjannet, S. Pareek et al., "Cellular processing of the nerve growth factor precursor by the mammalian proprotein convertases," Biochemical Journal, Vol. 314, no. 3, pp. 951-960, 1996.
45. R. H. Edwards, M. J. Selby, and W. J. Rutter, "Differential RNA splicing predicts two distinct nerve growth factor precursors," Nature, Vol. 319, no. 6056, pp. 784-787, 1986.
46. E. Dicou, J. Lee, and P. Brachet, "Synthesis of nerve growth factor mRNA and precursor protein in the thyroid and parathyroid glands of the rat," Proceedings of the National Academy of Sciences of the United States of America, Vol. 83, no. 18, pp. 7084-7088, 1986.
47. M. C. Caroleo, N. Costa, P. Tirassa, and L. Aloe, "Nerve growth factor produced by activated human monocytes/macrophages is severely affected by ethanol," Alcohol, Vol. 34, no. 2-3, pp. 107-114, 2004.
48. M.-L. Rogers, S. Bailey, D. Matusica et al., "ProNGF mediates death of Natural Killer cells through activation of the p75NTR-sortilin complex," Journal of Neuroimmunology, Vol. 226, no. 1-2, pp. 93-103, 2010.
49. Y. Chen, E. Dicou, and D. Djakiew, "Characterization of nerve growth factor precursor protein expression in rat round spermatids and the trophic effects of nerve growth factor in the maintenance of Sertoli cell viability," Molecular and Cellular Endocrinology, Vol. 127, no. 2, pp. 129-136, 1997.
50. A. W. Harrington, B. Leiner, C. Blechschmitt et al., "Secreted proNGF is a pathophysiological death-inducing ligand after adult CNS injury," Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, no. 16, pp. 6226-6230, 2004.
51. L. W. Chen, K. K. L. Yung, Y. S. Chan, D. K. Y. Shum, and J. P. Bolam, "The proNGF-p75NTR-sortilin signalling complex as new target for the therapeutic treatment of Parkinson's disease," CNS and Neurological Disorders - Drug Targets, Vol. 7, no. 6, pp. 512-523, 2008.
52. R. Vidaltamayo, C. M. Mery, A. Ángeles-Ángeles, G. Robles-Díaz, and M. Hiriart, "Expression of nerve growth factor in human pancreatic β cells," Growth Factors, Vol. 21, no. 3-4, pp. 103-107, 2003.
53. A. C. Cuello and M. A. Bruno, "The failure in NGF maturation and its increased degradation as the probable cause for the vulnerability of cholinergic neurons in Alzheimer's disease," Neurochemical Research, Vol. 32, no. 6, pp. 1041-1045, 2007.
54. E. Dicou, "High levels of the proNGF peptides LIP1 and LIP2 in the serum and synovial fluid of rheumatoid arthritis patients: evidence for two new cytokines," Journal of Neuroimmunology, Vol. 194, no. 1-2, pp. 143-146, 2008.
55. S. L. Elshaer, M. A. Abdelsaid, A. Al-Azayzih et al., "Pronerve growth factor induces angiogenesis via activation of trka: possible role in proliferative diabetic retinopathy," Journal of Diabetes Research, Vol. 2013, Article ID 432659, 10 pages, 2013.
56. NTR on the regulation of naturally occurring cell death and retinal ganglion cell number in the mouse eye," Developmental Biology, Vol. 290, no. 1, pp. 57-65, 2006.
57. S. V. McLennan, D. J. Kelly, M. Schache et al., "Advanced glycation end products decrease mesangial cell MMP-7: a role in matrix accumulation in diabetic nephropathy?" Kidney International, Vol. 72, no. 4, pp. 481-488, 2007.
58. C. R. Ban, S. M. Twigg, B. Franjic et al., "Serum MMP-7 is increased in diabetic renal disease and diabetic diastolic dysfunction," Diabetes Research and Clinical Practice, Vol. 87, no. 3, pp. 335-341, 2010.
59. N. P. E. Kadoglou, N. Sailer, G. Fotiadis, A. Kapelouzou, and C. D. Liapis, "The impact of type 2 diabetes and atorvastatin treatment on serum levels of MMP-7 and MMP-8," Experimental and Clinical Endocrinology and Diabetes, Vol. 122, no. 1, pp. 44-49, 2014.
60. L. Chilton, A. Middlemas, N. Gardiner, and D. R. Tomlinson, "The p75 neurotrophin receptor appears in plasma in diabetic rats - characterisation of a potential early test for neuropathy," Diabetologia, Vol. 47, no. 11, pp. 1924-1930, 2004.
61. P. M. Humpert, S. Kopf, Z. Djuric et al., "Levels of three distinct p75 neurotrophin receptor forms found in human plasma are altered in type 2 diabetic patients," Diabetologia, Vol. 50, no. 7, pp. 1517-1522, 2007.
62. M. P. Ferrari, F. Mantelli, M. Sacchetti et al., "Safety and pharmacokinetics of escalating doses of human recombinant nerve growth factor eye drops in a double-masked, randomized clinical trial," BioDrugs, Vol. 28, no. 3, pp. 275-283, 2014.